（文章来源：每日经济新闻） 每经AI快讯，海南自贸区板块盘初走低，康芝药业一度跌超7%，海德股份跌超6%，海南海药、海南瑞 泽、罗牛山跟跌。 ...

Core Viewpoint - Kangzhi Pharmaceutical (300086) announced the election of Mr. Gao Hongchang as the employee representative director of the company's seventh board of directors during the first employee representative meeting held on November 28, 2025 [1] Group 1 - The company held its first employee representative meeting on November 28, 2025 [1] - Mr. Gao Hongchang was elected as the employee representative director [1]

Group 1 - The hepatitis concept sector declined by 0.31%, ranking among the top declines in concept sectors, with companies like Zhongsheng Pharmaceutical and Guangji Pharmaceutical hitting the limit down [1][2] - Major stocks in the hepatitis sector that saw significant outflows include Zhongsheng Pharmaceutical with a net outflow of 684 million yuan, followed by Te Yi Pharmaceutical and Pian Zai Huang with net outflows of 112 million yuan and 81 million yuan respectively [2][3] - Conversely, stocks that experienced net inflows include Baihua Pharmaceutical, Huadong Medicine, and Kangzhi Pharmaceutical, with inflows of 97.75 million yuan, 43.11 million yuan, and 21.20 million yuan respectively [6] Group 2 - The top gainers in the hepatitis sector included Baihua Pharmaceutical, which rose by 10.01%, followed by Chengda Pharmaceutical and Kangzhi Pharmaceutical with increases of 4.79% and 3.00% respectively [1][6] - The overall market sentiment for the hepatitis sector appears negative, as evidenced by the significant net outflows and the number of stocks declining in value [2][3] - The trading volume for Zhongsheng Pharmaceutical was notably high, with a turnover rate of 18.78%, indicating active trading despite the price drop [2][3]

证券代码：300086 证券简称：康芝药业 公告编号：2025-058 康芝药业股份有限公司 关于选举产生第七届董事会职工代表董事的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 康芝药业股份有限公司（以下简称"公司"）第六届董事会任期即将届满，为 保证公司董事会的正常运行，根据《中华人民共和国公司法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等法律法规、规范性文件及《公司章程》的有关规定，公司于 2025 年 11 月 28 日召开了 2025 年第一次职工代表大会，经与会职工代表认真审议， 会议选举公司职工高洪常先生（简历详见附件）为公司第七届董事会职工代表董事。 高洪常先生的任职资格符合相关法律、法规规定，其将与公司 2025 年第一次 临时股东大会选举产生的八名非职工代表董事共同组成第七届董事会。公司第七届 董事会任期自公司 2025 年第一次临时股东大会审议通过之日（2025 年 12 月 9 日） 起三年。 高洪常先生当选公司职工代表董事后，公司第七届董事会拟兼任公司高级管理 ...

Market Overview - The chemical pharmaceutical sector increased by 0.02% on November 28, with Yifang Bio leading the gains [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] Top Gainers in Chemical Pharmaceutical Sector - Yifang Bio (688382) closed at 29.48, up 5.93% with a trading volume of 206,700 shares and a transaction value of 590 million [1] - Bibet (688759) closed at 34.88, up 5.47% with a trading volume of 115,300 shares [1] - Weier Pharmaceutical (603351) closed at 28.83, up 5.45% with a trading volume of 19,400 shares and a transaction value of 54.88 million [1] - Other notable gainers include Tingjian (002653) up 4.43% and Dongcheng Pharmaceutical (002675) up 3.53% [1] Top Losers in Chemical Pharmaceutical Sector - Guangji Pharmaceutical (000952) saw a significant decline of 9.98%, closing at 9.38 with a trading volume of 1,153,700 shares [2] - New Ganjing (920367) decreased by 5.73%, closing at 21.57 with a trading volume of 37,700 shares [2] - Hendi Pharmaceutical (301211) fell by 5.24%, closing at 15.19 with a trading volume of 310,700 shares [2] - Other notable losers include Beida Pharmaceutical (000788) down 3.80% and Fuyuan Pharmaceutical (6801089) down 3.71% [2] Fund Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 599 million from institutional investors, while retail investors saw a net inflow of 377 million [2] - Notable net inflows from retail investors were observed in stocks like Yifang Bio and Bibet, despite overall net outflows from institutional and speculative funds [3] Individual Stock Fund Flow - Yifang Bio had a net inflow of 57.86 million from institutional investors, but a net outflow from speculative and retail investors [3] - Huadong Pharmaceutical (000963) also saw a significant net inflow of 56.40 million from institutional investors, with outflows from speculative and retail investors [3] - Other stocks like Bibet and Dongcheng Pharmaceutical showed mixed fund flows, indicating varied investor sentiment [3]

Group 1 - The core viewpoint of the article highlights a collective decline in Hainan concept stocks within the A-share market, with significant drops observed across various companies [1][2]. Group 2 - Jingliang Holdings (000505) experienced a decline of 6.40%, with a total market capitalization of 5.525 billion [2]. - Shennong Seed Industry (300189) fell by 5.54%, with a market value of 5.765 billion [2]. - Hainan Haiyao (000566) decreased by 5.40%, having a market capitalization of 10.7 billion [2]. - Luoniushan (000735) saw a drop of 4.91%, with a market value of 9.822 billion [2]. - Hainan Mining (601969) declined by 4.22%, with a total market capitalization of 22.7 billion [2]. - Xinlong Holdings (000955) fell by 3.68%, with a market value of 3.666 billion [2]. - Kangzhi Pharmaceutical (300086) decreased by 3.47%, having a market capitalization of 5.698 billion [2]. - Jinpan Technology (688676) saw a decline of 3.18%, with a market value of 34.8 billion [2]. - Zhongtung High-tech (000657) dropped by 2.50%, with a market capitalization of 48.9 billion [2]. - Hainan Qiangsu (000886) experienced a decline of 2.02%, with a market value of 7.189 billion [2].

Market Performance - The ChiNext Index rose by 2.14%, closing at 3044.69 points, with a total trading volume of 529 billion yuan, an increase of 868 million yuan compared to the previous trading day [1] - Among the tradable ChiNext stocks, 407 stocks closed higher, with 15 stocks rising over 10%, including Yue Wannianqing, Kaichun Co., and Sanwei Tiandi, which hit the daily limit [1] - The average turnover rate for the ChiNext today was 4.13%, with 43 stocks having a turnover rate exceeding 20% [1] High Turnover Stocks - In the high turnover stocks, 23 stocks increased in price, with Kaichun Co., Huaren Health, and Saiwei Electronics leading the gains at 20.01%, 20.00%, and 16.27% respectively [2] - Conversely, stocks like Jianglong Shipbuilding, Fuchun Co., and Hongxiang Co. saw declines of 12.43%, 11.11%, and 9.43% respectively [2] Industry Analysis - The highest number of stocks with a turnover rate exceeding 20% belonged to the media and computer sectors, each having 7 stocks listed [3] - Among the high turnover stocks, 7 were featured on the Dragon and Tiger List, with institutional investors appearing in 6 of them [3] Fund Flow - A total of 17 high turnover stocks experienced net inflows of main funds, with Huaren Health, Kaichun Co., and Dali Kaipu seeing the highest net inflows of 140 million yuan, 122 million yuan, and 104 million yuan respectively [4] - The stocks with the largest net outflows included Tianhai Defense, BlueFocus, and Zhidema, with outflows of 332 million yuan, 331 million yuan, and 224 million yuan respectively [4] Performance Forecasts - Among the high turnover stocks, only one stock announced its full-year performance forecast for 2025, with a projected net profit increase of 2.76% for Nannetwork Digital, estimating a net profit of 586 million yuan [4]

Core Viewpoint - Kangzhi Pharmaceutical has received approval from the National Medical Products Administration for its traditional Chinese medicine "Cough Orange Granules" to conduct clinical trials for new indications [1] Summary by Categories Product Development - The approval allows the company to conduct clinical trials for the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD) with phlegm-heat obstructing the lungs [1] - "Cough Orange Granules" is already a product that has been produced and sold by the company, previously classified as a national secondary protected traditional Chinese medicine [1] Regulatory Approval - The clinical trial application was deemed to meet the requirements for drug registration, indicating a positive regulatory response to the company's submission [1] - The approval is based on the latest clinical research and expert consensus, showcasing the company's commitment to expanding the therapeutic applications of its products [1]

Core Viewpoint - The pharmaceutical sector is leading the market, while the consumer electronics sector is also performing actively, amidst a backdrop of fluctuating stock indices in China [1][3]. Sector Performance - The pharmaceutical sector is the top performer in the market, with notable activity in consumer electronics, semiconductors, and communication equipment sectors. Conversely, aerospace and military, banking, and chemical sectors are experiencing significant declines [3]. - Specific indices show that the SPD index increased by 2.94%, while the pharmaceutical index rose by 2.09%, indicating strong performance in these areas [4]. Stock Highlights - Anti-influenza stocks are seeing repeated activity, with companies like Yue Wannianqing hitting a 20% limit up, and Guangji Pharmaceutical achieving three consecutive trading limits. Other stocks such as Zhongheng Group and Kangzhi Pharmaceutical also reached their limits [5][9]. - The stock of Yue Wannianqing has a current price of 22.06, reflecting a 20.02% increase, with a total market capitalization of 3.517 billion [6][7]. Market Trends - As winter approaches, the flu season is becoming a focal point, with a significant increase in the purchase and attention towards antiviral medications. Data from Alibaba Health indicates that the number of buyers for flu-related medications surged over 500% in the last two weeks [9]. - The Hainan sector is also showing positive movement, with stocks like Hainan Ruize and Hainan Haiya achieving consecutive gains, supported by local government initiatives to enhance the economy and integrate into global supply chains [10][11].

Core Insights - The Hainan sector in the A-share market has shown significant activity, with multiple stocks experiencing notable gains, indicating a bullish trend in this region [1] Summary by Category Stock Performance - Kangzhi Pharmaceutical (康芝药业) saw an increase of 10.67%, with a total market capitalization of 6.185 billion and a year-to-date increase of 177.35% [2] - Hainan Ruize (海南瑞泽) and Hainan Haiyao (海南海药) both reached the daily limit up of 10%, with market capitalizations of 12 billion and 10 billion respectively [2] - Luoniushan (罗牛山) rose by 7.41%, with a market cap of 10.7 billion and a year-to-date increase of 39.78% [2] - Other notable performers include: - Xindazhou A (新大洲A) and Hainan Mining (海南矿业) both increased by over 4% [1] - Shennong Seed Industry (神农种业) rose by 4.49% with a market cap of 6.195 billion [2] - Haima Automobile (海马汽车) increased by 4.24%, with a market cap of 15.4 billion [2] - Hainan Rubber (海南橡胶) and Hainan Highway (海南高速) both saw increases of around 3.85% and 3.29% respectively [2] Market Trends - The MACD golden cross signal has formed, suggesting a positive momentum in the stock prices of these companies [1]